Intravenous human immunoglobulin utilization patterns and cost analysis in a Malaysian tertiary referral hospital

References

• United States Food & Drug Administration (FDA). Immune Globulin Intravenous (IGIV) Indications. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulin-intravenous-igiv-indications. Accessed 28 Nov 2021.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) rev 3. European Medicines Agency. 2018. https://www.ema.europa.eu/en/clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig. Accessed 28 Nov 2021.
   Google Scholar
• Bichuetti-Silva DC, Furlan FP, Nobre FA, Pereira CT, Gonçalves TR, Gouveia-Pereira M, et al. Immediate infusion related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol. 2014;23(2):442–446.
   PubMed Web of Science ®Google Scholar
• Dawoud T, Tatari H, Gebran N. A utilisation review of intravenous immunoglobulin in a tertiary care hospital in United Arab Emirates. Eur J Hosp Pharm Sci Pract. 2012;19(3):286–288.
   Google Scholar
• Burt RK, Tappenden P, Balabanov R, et al. The cost effectiveness of immunoglobulin vs hematopoietic stem cell transplantation for CIDP. Front Neurol. 2021;2021(12): 645263.
   Google Scholar
• Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US Academic Health Centers. Ann Pharmacother. 2000;2000(34):295–299.
   Google Scholar
• Fakhari Z, Farsaei S, Sabzghabaee AM. Predicting factors for the pattern of intravenous immunoglobulin utilization in a Middle Eastern University Hospital. J Res Pharm Pract. 2018;7(4):188–194.
   PubMed Web of Science ®Google Scholar
• MOHM Formulary. https://www.pharmacy.gov.my/v2/en/apps/fukkm?generic=human+&category=&indications=
   Google Scholar
• Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3):S1–S46.
   PubMed Web of Science ®Google Scholar
• Pendergrast JM, Sher GD, Callum JL. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995–2000. Vox Sang. 2005;89(3):150–160.
   PubMed Web of Science ®Google Scholar
• Badia M, Cardona L, Massanes R. Changes in the pattern of intravenous immunoglobulin use over a 5-year period. Eur J Hosp Pharm. 2006;2006(12):67–71
   Google Scholar
• Alangari AA, Abutaleb MH, Albarraq AA, et al. Intravenous immunoglobulin utilization in a tertiary care teaching hospital in Saudi Arabia. Saudi Med J. 2008;29(7):975–979.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017. https://doi.org/10.1007/s00134-017-4683-6.
   Web of Science ®Google Scholar
• Jarczak D, Kluge S, Nierhaus A. Use of intravenous immunoglobulins in sepsis therapy—a clinical view. Int J Mol Sci. 2020;2020(21):5543.
   Google Scholar
• Justiz Vaillant A. A female with systemic lupus erythematosus and Streptococcal pneumonia treated with intravenous immunoglobulins (IVIg). Preprints 2020, 2020090544. https://doi.org/10.20944/preprints202009.0544.v1
   Google Scholar
• Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005;29:219–228.
   PubMed Web of Science ®Google Scholar
• Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396–414. https://doi.org/10.1128/CMR.00001-09.
   PubMed Web of Science ®Google Scholar
• Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol. 2005;66(4):403–410. https://doi.org/10.1016/j.humimm.2005.01.029.
   PubMed Web of Science ®Google Scholar
• Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F. Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Adv. 2022;6(3):785–792. https://doi.org/10.1182/bloodadvances.2021005627.
   PubMed Web of Science ®Google Scholar
• Castle D, Robertson NP. Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2019;266(9):2338–2340. https://doi.org/10.1007/s00415-019-09485-9.
   PubMed Web of Science ®Google Scholar